NCT06074692View on ClinicalTrials.gov

PARP Inhibition, Stereotactic Body Radiotherapy and Immunotherapy for Metastatic or Advanced Sarcoma (PRIMA)

PHASE2RecruitingINTERVENTIONAL
Enrollment

86

Participants

Timeline

Start Date

June 1, 2023

Primary Completion Date

August 30, 2026

Study Completion Date

December 30, 2026

Conditions
SarcomaSarcoma,Soft TissueSarcoma of Bone
Interventions
COMBINATION_PRODUCT

Camrelizumab and fluzoparib with concurrent stereotactic body radiotherapy (SBRT)

Patients receive Camrelizumab (PD-1 inhibitor) and fluzoparib (PARP inhibitor) with concurrent stereotactic body radiotherapy (SBRT)

Trial Locations (1)

20025

RECRUITING

Ruijin Hospital, Shanghai Jiao Tong University, School of Medicine, Shanghai

All Listed Sponsors
lead

Ruijin Hospital

OTHER